Mylan's most recent trend suggests a bearish bias. One trading opportunity on Mylan is a Bear Call Spread using a strike $47.00 short call and a strike $52.50 long call offers a potential 13.64% return on risk over the next 38 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $47.00 by expiration. The full premium credit of $0.66 would be kept by the premium seller. The risk of $4.84 would be incurred if the stock rose above the $52.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Mylan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Mylan is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Mylan
Meda Falls Most Since Rejecting Mylan on Lowered Sales Forecast
Wed, 13 Aug 2014 11:20:55 GMT
Mylan Launches Generic Xeloda® Tablets
Mon, 11 Aug 2014 15:10:59 GMT
noodls – PITTSBURGH , Aug. 11, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. …
Mylan Launches Generic Xeloda® Tablets
Mon, 11 Aug 2014 11:30:00 GMT
PR Newswire – PITTSBURGH, Aug. 11, 2014 /PRNewswire/ — Mylan Inc. (MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.(1) CEO Heather Bresch commented, “The approval of this product, one of a number of key approvals that had been pending with FDA, adds an important product to our broad and growing oncology franchise.
Salix Q2 Misses Estimates; Novo Nordisk, Mylan Slide
Thu, 07 Aug 2014 22:50:00 GMT
Why Mylan (MYL) Stock Is Dropping Today
Thu, 07 Aug 2014 19:20:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook